VanEck Pharmaceutical ETF
PPH
102 hedge funds and large institutions have $405M invested in VanEck Pharmaceutical ETF in 2023 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 13 closing their positions.
392% more call options, than puts
Call options by funds: $551K | Put options by funds: $112K
44% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 25
8% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 13
3% more capital invested
Capital invested by funds: $392M → $405M (+$12.6M)
0% more funds holding
Funds holding: 102 → 102 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
12.44% less ownership
Funds ownership: 107.35% → 94.91% (-12%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$42.9M |
| 2 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
+$12.3M |
| 3 |
JP Morgan Chase
New York
|
+$12.1M |
| 4 |
IAA
Independent Advisor Alliance
Charlotte,
North Carolina
|
+$3.96M |
| 5 |
Morgan Stanley
New York
|
+$2.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$27.9M |
| 2 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$22.8M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$12M |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$3.71M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2.51M |
PPH Hedge Fund Activity: Q3 2023 in Review
102 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q3 2023, worth a combined $405M — up 3.2% from $392M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new PPH positions and 13 closed out — a net gain of 1 holder — while 36 added to existing stakes and 25 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $42.9M. The largest seller was Bank of America, cutting an estimated $27.9M.
- 102 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $405M of VanEck Pharmaceutical ETF stock for Q3 2023, up 3.2% quarter-over-quarter.
- 14 funds opened new VanEck Pharmaceutical ETF positions in Q3 2023 and 13 closed out, a net change of +1 holder.
- The largest VanEck Pharmaceutical ETF buyer in Q3 2023 was Goldman Sachs, an estimated $42.9M added.
- The largest VanEck Pharmaceutical ETF seller in Q3 2023 was Bank of America, an estimated $27.9M sold.
Based on aggregated 13F filings for Q3 2023.